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Abstract—Accelerometry has been recognized as a method of 
objectively measuring community ambulation in persons with 
multiple sclerosis (MS). However, the assumption that walking 
itself serves as a major contributor to the accelerometer signal 
has yet to be tested. This study examined the assumption that 
community-based walking is a primary contributor to acceler-
ometer output in MS. Ambulatory persons (5 males/17 females; 
13 without aid/9 with aid) with MS wore a triaxial accelerome-
ter (ActiGraph GT3X, Health One Technologies; Fort Walton 
Beach, Florida) as well as an IDEEA system (MiniSun, Inc; 
Fresno, Florida) over the course of a single day. Outcome mea-
sures for the accelerometer included movement counts/hour for 
the vertical, anterior-posterior, and mediolateral axes. Outcomes 
for the IDEEA system included percent time walking, sitting, 
and standing, as well as walking speed. Pearson product corre-
lations (r) were used to examine the associations between out-
comes from the accelerometer and IDEEA system. Significant 
correlations were observed between percent walking time and 
movement counts/hour along the vertical (r = 0.84) and ante-
rior-posterior (r = 0.69) axes. Significant correlations were fur-
ther noted between movement counts/hour along the vertical 
axis and walking speed (r = 0.45) and self-report walking 
impairment (r = 0.50) and disability (r = 0.46). Such obser-
vations further support accelerometry as an objective marker of 
community ambulation in persons with MS.
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INTRODUCTION
The loss of walking is a common consequence of 
multiple sclerosis (MS). Nearly 85  percent of persons 
with MS identify walking problems as a primary limita-
tion that affects functioning and activities of daily living 
[1–2]. By extension, the measurement of walking has 
become an important outcome in clinical research and 
practice in this population [3].
Accelerometry has been identified as an objective 
measure of community walking in neurological disorders, 
including MS [4–6]. This is important because most mea-
sures of walking in MS are performed in laboratory or 
clinical settings and suffer from poor ecological or real-
world validity. Nevertheless, the application of acceler-
ometry as an objective measure of community ambulation 
in MS rests on several tested and untested assumptions. 
Abbreviations:  AP = anterior-posterior, EDSS = Expanded 
Disability Status Scale, ML = mediolateral, MS = multiple 
sclerosis, MSWS-12 = Multiple Sclerosis Walking Scale-12, 
SD = standard deviation.
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Existing data indicate that movement or activity counts 
from an accelerometer worn around the waist capture 
inter- and intraindividual variation in overground walking 
within a clinical setting [7], accelerometer movement or 
activity counts over a 7 d period are associated with spa-
tiotemporal parameters of gait [8], and walking is a pri-
mary self-selected physical activity among persons with 
MS [9]. One of the most important untested assumptions 
is that community walking itself is a major contributor to 
the accelerometer signal in persons with MS. There are 
no extant data indicating that the accelerometry signal 
results predominantly from community walking in per-
sons with MS. To that end, this investigation examined 
the association between community-based walking and 
movement (e.g., activity) counts recorded by a waist-
worn accelerometer in persons with MS.
METHODS
Participants
The sample comprised 22 ambulatory persons
(5 males/17 females) with a definite diagnosis of MS con-
sistent with Poser and/or McDonald criteria [10–12]. 
Demographic information is provided in Table 1. Partici-
pants ranged in age from 23 to 64 yr with a mean of 46.9 yr 
(standard deviation [SD] = 11.7 yr). The average time since 
diagnosis was 11.0 yr (SD = 6.9 yr). Nine (41% of the sam-
ple) of the participants used a cane during testing as well as 
in everyday life. The sample had a range of Expanded Dis-
ability Status Scale (EDSS) scores between 0 and 6.0 (inter-
quartile range = 2.5; median = 3.0).
Procedures
Upon arrival at the laboratory, participants provided 
demographic information and completed the self-reported 
EDSS [13–14] and the Multiple Sclerosis Walking Scale-
12 (MSWS-12) [15]. The participants were then outfitted 
with a waist-worn triaxial accelerometer (ActiGraph
GT3X, Health One Technologies; Fort Walton Beach, 
Florida) and an IDEEA system (MiniSun, Inc; Fresno, 
Florida). The GT3X accelerometer contains a solid-state, 
digital accelerometer that generates an electrical signal 
proportional to the force acting on it along three axes. The 
IDEEA system consists of 5 uniaxial accelerometers 
placed on the plantar surfaces of each foot, the anterior 
portions of each thigh, and centered on the sternum. Based 
on the activation pattern of the accelerometers, the accom-
panying software is capable of determining behaviors such 
as sitting, standing, and walking. The IDEEA system has 
evidence for its reliability and validity in both nondisabled 
and pathological populations [16–20]. Participants arrived 
at our laboratory early in the morning to accumulate a full 
day’s wear time of the accelerometers. Once outfitted with 
both the triaxial accelerometer and the IDEEA system, 
participants continued with a normal daily routine. Partici-
pants were instructed not to deviate from normal daily 
activities. Participants returned to the laboratory in the eve-
ning and had the equipment removed.
Data and Statistical Analysis
Table 1.
Demographics of 22 participants with multiple sclerosis.
Variable Mean Standard Deviation Minimum Maximum
Age (yr) 46.9 11.7 23 64
Yr-Dx 11.0 6.9 1.0 23.0
EDSSSR (median IQR) 3.0 2.5 1.0 6.0
Assistive Device Usage (%) 41 NA NA NA
EDSSSR = self-report Expanded Disability Status Scale, IQR = interquartile range, NA = not applicable, Yr-DX = years since diagnosis.
Outcome measures for the accelerometer included 
activity counts/hour for the vertical, anterior-posterior 
(AP), and mediolateral (ML) axes. While step counts 
derived from an accelerometer are traditionally used to 
quantify physical activity levels, they only measure 
whether a step has taken place without providing infor-
mation regarding the quality of the step. In contrast, 
activity counts took into account the binary event of a 
step as well as the quality/intensity of the step. Outcomes 
for the IDEEA system included percent time walking, sit-
ting, and standing as well as walking speed (meters/min-
ute). All analyses were completed using SPSS version 
17.0 (IBM; Armonk, New York) and significance was 
noted at p < 0.05. Means and SD were calculated for all 
outcome measures. Pearson product correlations (r) were 
used to examine the association between activity counts1407
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and behavior (e.g., walking, standing, and sitting). Values 
are reported as mean ± SD.
RESULTS
Wear times for the devices ranged from 6.0 to 10.1 h 
and average 7.6 ± 1.6 h. Mean activity counts/hour along the 
vertical, AP, and ML axes were 10,938 ± 6,313, 15,803 ± 
6,583, and 17,253 ± 7,684, respectively. Participants sat 
61.3 ± 16.9 percent, stood 23.6 ± 13.8 percent, and walked 
5.7 ± 3.6 percent of the time. Mean walking speed was 
57.6 ± 13.2 m/min. Mean self-perceived walking impair-
ment was 40.3 ± 26.5 based on MSWS-12 scores.
As reported in Table 2, percent time spent walking was 
significantly correlated with activity counts along the verti-
cal (r = 0.84) and AP (r = 0.69), but not ML (r = 0.40), 
axes. Percent sitting was significantly associated with activ-
ity counts along the AP (r = 0.54) and ML (r = 0.64), but 
not vertical (r = 0.39), axes. Percent standing was signifi-
cantly correlated with movement counts along the ML axis 
(r = 0.63). Only movement counts along the vertical axis 
were significantly associated with walking speed (r = 0.45), 
self-reported EDSS scores (r = 0.46), and MSWS-12 
scores (r = 0.50). The amount of walking and walking 
speed were further associated with self-reported EDSS 
scores (r = 0.51 and 0.57, respectively) and MSWS-12 
scores (both 0.49).
DISCUSSION
This investigation tested the assumption that a waist-
worn accelerometer captures community walking behav-
ior in persons with MS. To that end, the primary novel 
results were that activity counts along the vertical axis 
were associated with time spent walking as well as walk-
ing speed, disability status, and self-reported walking 
impairment. Collectively, this further indicates that accel-
erometry provides an objective measure of community 
ambulation in MS.
Conceptually, the degree of walking impairment in MS 
depends on the interplay among pathological, physiological, 
personal, and environmental parameters [6]. Yet, researchers 
and clinicians routinely measure walking impairment using 
the 500 m walk of the EDSS and timed walk tests [21–24]. 
The primary limitation of those measures involves perfor-
mance under controlled, static circumstances. Such condi-
tions reflect the effect of pathological, physiological, and 
personal factors on ambulatory impairment but do not 
account for additive influence of community or environ-
mental factors. Consequently, those measures fail to reliably 
capture impairments in community-based ambulation. By 
comparison, the results from the current study suggest that 
accelerometry can capture the amount and quality of walk-
ing (e.g., speed) in a real-world environment. When consid-
ering the results of this study along with previous research 
[4,6–7,9], substantial evidence exists supporting the appli-
cation of commercially available, waist-worn accelerome-
ters for measuring community-based ambulation in persons 
with MS.
Table 2.
Correlation coefficients between accelerometer, motor behavior, and disability.
Variable Sitting (%) Standing (%) Walking (%) Walking Speed MSWS-12 EDSSSR
Vertical 0.39 0.26 0.84* 0.45* 0.50* 0.46*
AP 0.54* 0.37 0.69* 0.01 0.15 0.20
ML 0.64* 0.63* 0.40 0.23 0.18 0.08
Sitting (%) — 0.80* 0.28 0.11 0.16 0.09
Standing (%) — — 0.19 0.11 0.06 0.09
Walking (%) — — 0.27 0.49* 0.51*
Walking Speed — — — — 0.49* 0.57*
MSWS-12 — — — — — 0.86*
*p < 0.05.
AP = anterior-posterior axis of GT3X accelerometer, EDSSSR = self-report Expanded Disability Status Scale, ML = mediolateral axis of GT3X accelerometer, 
MSWS-12 = Multiple Sclerosis Walking Scale-12, Vertical = vertical axis of GT3X accelerometer.
The findings of this study extend research examining 
accelerometry as an objective marker of walking impairment. 
For instance, data indicate that a waist-worn accelerometer 
is sensitive to intra- and interindividual variation in1408
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walking speed [7] and that accelerometer data collected over 
a 7 d period are related to gait kinematics [8]. Taking this into 
consideration, the results from the present study further sug-
gest that accelerometry is an objective marker of community 
walking in MS because counts/hour along the vertical axis 
were associated with community-based ambulation captured 
by the IDEEA system.
Despite the novelty of the present findings, this 
investigation had some limitations. One of the limitations 
was that the results are dependent on the algorithm 
implemented by the IDEEA system to determine walking 
behavior. It is possible that implementation of a different 
algorithm to detect walking in the acceleration profiles of 
the IDEEA system could change the association between 
the amount and quality of walking in MS and the output 
of the ActiGraph accelerometer. Additionally, data col-
lection was limited to a single day of testing, excluding 
the examination of day to day variations. Lastly, given 
that the sample had on average a relatively low level of 
disability (median EDSS of 3.0), the current observations 
may not apply to those with greater disability. Although 
this is a limitation, it is important to note that 41 percent 
of the current sample used an assistive device during 
walking and that the current observations are likely to 
extend to those with greater impairment. Further work is 
necessary to examine this possibility.
CONCLUSIONS
The novel findings of this investigation are that the 
vertical signal from a commercially available, three-
dimensional, waist-worn accelerometer is related to the 
amount and quality of walking in a real-world environ-
ment in persons with MS. Combined with recent research 
on accelerometry and walking impairment, the current 
results indicate that accelerometry provides an objective 
marker of walking impairments that occur within the 
community among persons with MS. Future work is 
needed to determine whether accelerometry is sensitive 
to changes in gait as a function of disease, rehabilitation, 
pharmaceutical treatment, and/or disability progression.
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